Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome | MicrobiomeTrials← Back to trialsNCT02996448
Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2016-11-17Est. Completion: 2018-07-22
Enrollment target: 3 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Hyper IgE Syndrome From STAT3 MutationJob s SyndromeHIESLupusAtopic Dermatitis
Background:
Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects …
Bethesda, United StatesEst. completion May 1, 2030
InfectionsPneumoniaImmune System DiseasesSTAT3 Transcription FactorJob Syndrome
The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections…